<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:30:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10471938" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10471938</identifier>
        <datestamp>2023-09-02</datestamp>
        <setSpec>bloodadv</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
              <journal-title-group>
                <journal-title>Blood Advances</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2473-9529</issn>
              <issn pub-type="epub">2473-9537</issn>
              <publisher>
                <publisher-name>The American Society of Hematology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10471938</article-id>
              <article-id pub-id-type="pmcid">PMC10471938</article-id>
              <article-id pub-id-type="pmc-uid">10471938</article-id>
              <article-id pub-id-type="pmid">37379264</article-id>
              <article-id pub-id-type="pii">S2473-9529(23)00357-9</article-id>
              <article-id pub-id-type="doi">10.1182/bloodadvances.2022009467</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Lymphoid Neoplasia</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Burack</surname>
                    <given-names>W. Richard</given-names>
                  </name>
                  <email>richard_burack@urmc.rochester.edu</email>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Li</surname>
                    <given-names>Hongli</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Adlowitz</surname>
                    <given-names>Diana</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Spence</surname>
                    <given-names>Janice M.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Rimsza</surname>
                    <given-names>Lisa M.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Shadman</surname>
                    <given-names>Mazyar</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Spier</surname>
                    <given-names>Catherine M.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Kaminski</surname>
                    <given-names>Mark S.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Leonard</surname>
                    <given-names>John P.</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Leblanc</surname>
                    <given-names>Michael L.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Sonali M.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Friedberg</surname>
                    <given-names>Jonathan W.</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <aff id="aff1"><label>1</label>Department of Pathology, University of Rochester Medical Center, Rochester, NY</aff>
                <aff id="aff2"><label>2</label>Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA</aff>
                <aff id="aff3"><label>3</label>Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, AZ</aff>
                <aff id="aff4"><label>4</label>Department of Pathology, The University of Arizona, Tuscon, AZ</aff>
                <aff id="aff5"><label>5</label>Department of Internal Medicine, University of Michigan, Ann Arbor, MI</aff>
                <aff id="aff6"><label>6</label>Department of Medicine, Weill Cornell Medical College, New York, NY</aff>
                <aff id="aff7"><label>7</label>Department of Medicine, University of Chicago School of Medicine, Chicago, IL</aff>
                <aff id="aff8"><label>8</label>Department of Medicine, University of Rochester Medical Center, Rochester, NY</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Correspondence: W. Richard Burack, Department of Medicine, University of Rochester, Pathology and Laboratory Medicine, 601 Elmwood Ave, Box 626, Rochester, NY 14642; <email>richard_burack@urmc.rochester.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>30</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <day>12</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>30</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <volume>7</volume>
              <issue>17</issue>
              <fpage>5082</fpage>
              <lpage>5090</lpage>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>6</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>The American Society of Hematology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract abstract-type="author-highlights" id="abs0010">
                <title>Key Points</title>
                <p>
                  <list list-type="simple" id="ulist0010">
                    <list-item id="u0010">
                      <label>•</label>
                      <p id="p0010">In a phase 3 clinical trial of FL, AICDA-mediated intraclonal heterogeneity was not prognostic.</p>
                    </list-item>
                    <list-item id="u0015">
                      <label>•</label>
                      <p id="p0015">TP53 mutated populations are common, subclonal, and their absence confers sensitivity to a radiation-containing regimen.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="graphical" id="abs0015">
                <title>Visual Abstract</title>
                <fig id="undfig1" position="anchor">
                  <graphic xlink:href="BLOODA_ADV-2022-009467-ga1"/>
                </fig>
              </abstract>
              <abstract id="abs0020">
                <title>Abstract</title>
                <p>Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in &lt;5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal <italic>TP53</italic> mutations (median allele frequency 0.02) were found in 25% of diagnostic FL specimens and in 27% of a separate validation cohort. In the R-CHOP arm, pathogenic <italic>TP53</italic> mutations were not associated with progression-free survival (PFS) (10-year PFS 43% vs 44%). In contrast, among patients with no detectable pathogenic <italic>TP53</italic> mutation, RIT-CHOP was associated with a longer PFS than with R-CHOP (10-year PFS 67% vs 44%; hazard ratio = 0.49; <italic>P</italic> = .008). No relationship was detected between PFS and the extent of activation-induced cytidine deaminase (AICDA)–mediated heterogeneity. In summary, subclonal <italic>TP53</italic> mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. The absence of a detectable subclonal mutation in <italic>TP53</italic> defined a population that particularly benefited from RIT.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="sec1">
              <title>Introduction</title>
              <p id="p0020">Follicular lymphoma (FL) is a mature B-cell neoplasm whose cell-of-origin, the germinal center B cell, expresses activation-induced cytidine deaminase (AICDA) which physiologically targets the immunoglobulin genes. Aberrant targeting of AICDA to other genes creates not only innumerable passenger mutations but may also create a smaller number of additional driver mutations that lead to progression.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> This hypothesis suggests that greater apolipoprotein B messenger RNA–editing enzyme, catalytic polypeptide–mediated genetic heterogeneity will be associated with a greater likelihood of tumor evolution. Previous studies of FL have yielded a range of conclusions regarding relationships among AICDA expression, AICDA-mediated mutations, tumor heterogeneity, and outcomes.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref></p>
              <p id="p0025">Although <italic>TP53</italic> is the most commonly mutated gene in human cancers, mutations are reported in &lt;5% of pretreatment FL specimens.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> In contrast, <italic>TP53</italic> is reported to be mutated in ∼20% of transformed and/or relapsed FL specimens. This disparity suggests that <italic>TP53</italic>-mutated subpopulations, which are too small for detection, might be present at the time of diagnosis in tumors destined to relapse. There is precedence for the clinical significance of subclonal, <italic>TP53</italic>-mutated populations; for example, in chronic lymphocytic leukemia, the median variant allele frequency (VAF) of <italic>TP53</italic> mutations is 0.02 at the time of detection, and any detectable subclonal <italic>TP53</italic> mutation, regardless of VAF, is associated with shorter progression-free survival (PFS) after immunochemotherapy.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p>
              <p id="p0030">To investigate the impact of genetic heterogeneity, we developed a deep-sequencing assay to quantify subclonal mutations in archival formalin-fixed paraffin-embedded (FFPE) specimens and applied this assay to a National Clinical Trials Network phase 3 trial in FL with mature results, SWOG (formerly Southwest Oncology Group) S0016 (<ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov" id="PC_linkQKF3PFBzDv">www.clinicaltrials.gov</ext-link>; accessed April 2021). In this study, we used SWOG 0016 to test if 2 forms of heterogeneity, which are driven by AICDA and marked by dysfunctional <italic>TP53</italic>, are associated with outcomes in the setting of chemotherapy combined either with immunotherapy or with radioimmunotherapy (RIT).<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></p>
            </sec>
            <sec id="sec2">
              <title>Methods</title>
              <p id="p0035">SWOG and Alliance (formerly Cancer and Leukemia Group B) compared 2 immunochemotherapy regimens R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone) vs CHOP followed by consolidation with iodine I-131 tositumomab RIT-CHOP) in a phase 3 randomized intergroup protocol (SWOG S0016), enrolling 554 patients with untreated, advanced-stage FL (bulky stage II, III, or IV; any grade) between 1 March 2001 and 15 September 2008.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> FFPE diagnostic specimens were submitted for central banking but were not required for enrollment.<fig id="fig1"><label>Figure 1.</label><caption><p><bold><italic>TP53</italic> mutations are common in S0016 FL specimens and have a low VAF.</bold> (A) The pathogenic mutations detected in S0016 include canonical hotspots for <italic>TP53</italic> mutations. The location and numbers of mutations at each site are indicated as missense (orange) or nonsense mutations (cyan). The colored regions indicate assigned functionality of each protein domain (from left, transactivation 1, transactivation 2, proline-rich domain, DNA binding, hinge domain, oligomerization domain, and alpha domain). (B) The median VAF of pathogenic mutations in FL is low. In the 37 of 147 FL specimens with a pathogenic <italic>TP53</italic> mutation, the median VAF for these mutations is 0.02 (FL). In a validation set, 28 mutations were detected in 19 specimens (FL validation) with a median VAF of 0.03. Additional control samples of MZL and mantle cell lymphoma MCL (36 and 38 specimens) have a substantially higher median VAF. Boxes contain second and third quartiles, and whiskers 10 to 90 percentiles. Specimens with a single detectable mutation are noted with black squares. For specimens with &gt;1 <italic>TP53</italic> mutation, all the mutations in that specimen share a unique symbol.</p></caption><graphic xlink:href="BLOODA_ADV-2022-009467-gr1"/></fig><fig id="fig2"><label>Figure 2.</label><caption><p><bold><italic>TP53</italic> mutations are prognostic in S0016 and specifically affect the prognosis on the RIT-CHOP arm but not on the R-CHOP arm.</bold> Of 147 patients, 72 showed disease progression and 44 died with a median of 15 years follow-up among those last known alive. (A,B) Mutations in <italic>TP53</italic> were associated with shortened PFS in S0016 but not OS. (C,D) <italic>TP53</italic> mutations affected PFS on RIT-CHOP arm but not on the R-CHOP arms (blue, no mutation detected; red, mutation detected).</p></caption><graphic xlink:href="BLOODA_ADV-2022-009467-gr2"/></fig><fig id="fig3"><label>Figure 3.</label><caption><p><bold>In patients with NO detectable <italic>TP53</italic> mutation, CHOP-RIT is associated with longer PFS.</bold> (A) There is a trend to longer PFS with CHOP-RIT similar to that previously published for the entire study.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> (B) Removing the 37 patients with TP53 mutations, the PFS was significantly longer on the RIT-CHOP arm compared with the R-CHOP arm. (C) In the subset of 37 patients with a <italic>TP53</italic> mutation, there is an opposite trend with shortened PFS on the RIT-CHOP arm. (Red, RIT-CHOP; Blue R-CHOP).</p></caption><graphic xlink:href="BLOODA_ADV-2022-009467-gr3"/></fig></p>
              <p id="p0040">An independent validation cohort consisted of 75 FFPE B-cell non-Hodgkin lymphoma specimens from 37 patients diagnosed with FL, enrolled in 1 of several SWOG clinical trials in B-cell non-Hodgkin lymphoma (S0016, S0433, S0801, and S0433) and treated at the University of Rochester. Of these, 30 patients had a pretreatment FL specimen.</p>
              <p id="p0045">Eighty-five specimens (11 nodular lymphocyte predominant Hodgkin lymphoma [nLPHL], 38 mantle cell lymphomas [MCL], 36 marginal zone lymphoma [MZL] specimens) served as methodologic controls. These specimens were processed identically to the FL specimens and analyzed using the same pipeline.</p>
              <p id="p0050">The polymerase chain reaction (PCR) strategy in this study includes 2 features to allow high sensitivity while suppressing false discovery owing to a range of sources (refer to <xref rid="appsec1" ref-type="sec">supplement for rationale, methods, and data</xref>). First, genomic template concentration is as high as achievable in order to detect low frequency sequence variants and to bias early rounds of PCR to use guide DNA (gDNA) as template. Second, we use an internal control sequence (eukaryotic ultraconserved region [eUCR]), to provide specimen- and sequence-specific thresholds for false discovery to account for PCR amplification-related errors and formalin-induced sequence alterations. We validated the reproducibility of the methods and showed that the results are not meaningfully affected by repair of formalin-associated DNA lesions and are independent of PCR-cycle number (refer to <xref rid="appsec1" ref-type="sec">supplemental Results and Methods</xref>).</p>
              <p id="p0055">Each specimen fulfilled the following criteria: (1) sufficient DNA for 4 multiplexed PCR-reactions each with 250 ng gDNA to allow amplification of the <italic>TP53</italic> (all exons), the 5′ UTR of <italic>BCL2</italic> (uBCL2, a region of the gene with particularly high numbers of passenger mutations that is reliably amplifed)<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and the clonal IGHV gene and (2) appropriate size distribution of DNA products after library preparation (∼300 base pairs)</p>
              <p id="p0060">To obtain a false discovery rate of 1% for single nucleotide variants (SNV) with a VAF = 0.002, each multiplex reaction included an amplicon of eUCR41 to provide specimen-, reaction-, and sequence-specific metrics of DNA-damage and sequencing noise. Ultradeep, amplicon-based sequencing (∼10 000×) (Ilumina 300 nt paired end) were merged, mapped to reference, and SNV were called using LoFreq based on individualized error thresholds (derived from the eUCR41 amplicon; refer to <xref rid="appsec1" ref-type="sec">supplemental Methods</xref>).</p>
              <p id="p0065"><italic>TP53</italic> sequence variants were classified as pathogenic when both the Seshat and International Agency for Research on Cancer databases concurred that the variant was likely associated with cancer.</p>
              <p id="p0070">PFS was defined as the time from date of registration to the date of first observation of progressive disease or death owing to any cause. Patients last known to be alive and progression-free were censored at the date of last contact. Cox regression model was used to estimate hazard ratio (HR) and 95% confidence interval (CI).</p>
              <p id="p0075">For clarity, VAF are expressed in decimal format (range 0-1, in which 0.05 corresponds to 5%) and fraction of specimens affected are expressed in percentage format.</p>
            </sec>
            <sec id="sec3">
              <title>Results</title>
              <p id="p0080">Diagnostic biopsies were available for 230 of 571 enrollees in SWOG S0016. DNA and sequence data from 147 samples (<italic>TP53</italic> 147, <italic>BCL2</italic> 146, and IGHV 120) fulfilled the quality metrics (refer to "Methods” and <xref rid="appsec1" ref-type="sec">supplement for CONSORT [Consolidated Standards of Reporting Trials] diagram</xref>). For patients with (147) and without (389) completed sequencing, the median duration of follow-up (both 14.7 years), the number of patients who experienced progression of disease or died (both 58%), and other patient characteristics (demographics, histology, stage, FLIPI, treatment arm, and PFS) were comparable (with the exception of serum β-2 microglobulin) (<xref rid="appsec1" ref-type="sec">supplemental Table 1</xref>).</p>
              <sec id="sec3.1">
                <title>Twenty-five percent of FL specimens from patients with untreated advanced-stage disease have a <italic>TP53</italic> mutation</title>
                <p id="p0085">The 147 FFPE specimens from S0016 (80 RIT-CHOP; 67 R-CHOP) had 51 mutations within <italic>TP53</italic>; the variants in 37 patients (25%) created missense or nonsense mutations that met established criteria for pathogenicity (<xref rid="fig1" ref-type="fig">Figure 1</xref>A; <xref rid="appsec1" ref-type="sec">supplemental Table 2</xref>). With the exception of sex, clinical characteristics at presentation of patients with and without <italic>TP53</italic> mutations were indistinguishable (males were overrepresented in the nonmutated group; <xref rid="appsec1" ref-type="sec">supplemental Table 3</xref>).</p>
              </sec>
              <sec id="sec3.2">
                <title>Pathogenic <italic>TP53</italic> mutations in FL are typically subclonal and often multiple</title>
                <p id="p0095">In the initial data set, the VAFs for pathogenic <italic>TP53</italic> mutations ranged from 0.009 to 0.74 (median 0.02) (<xref rid="fig1" ref-type="fig">Figure 1</xref>B). Twenty-six samples had a single mutation whereas 11 had &gt;1 (8 with 2 and 3 with 3 mutations). In the validation set of 75 samples from a total of 37 patients, 14 samples (19%) had 28 pathogenic TP53 mutation with a median VAF of 0.03 (range 0.01-0.44). To assess if the low VAFs of <italic>TP53</italic> mutations in FL specimens might be because of nonspecific artifacts associated with PCR or the analytical pipeline, we assayed 85 samples from 3 other B-cell lymphomas, MCL (38), in which <italic>TP53</italic> mutations have been reported to be predominantly clonal,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> MZL (36), and nLPHL (11). No mutations were detected in the 11 nLPHL specimens. In contrast to FL, <italic>TP53</italic> mutations in MCL and MZL had a median VAF of 0.32, indicating that the abundance of low VAF mutations in the FL specimens is not due to processing artifacts (<xref rid="fig1" ref-type="fig">Figure 1</xref>B).</p>
              </sec>
              <sec id="sec3.3">
                <title>Subclonal <italic>TP53</italic> mutation status affects progression only in patients treated with RIT-CHOP</title>
                <p id="p0100">Although almost all the mutations were subclonal, pathogenic <italic>TP53</italic> mutations were associated with a shortened PFS (HR = 1.73; <italic>P</italic> = .0183; 95% CI for HR, 1.10-2.72) (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). In contrast, no impact was seen on PFS in the CHOP-R arm (10-year PFS 43% vs 44%) (<xref rid="fig2" ref-type="fig">Figure 2</xref>C); the effect of mutation status on the PFS seen in the full-study population (<xref rid="fig2" ref-type="fig">Figure 2</xref>A) is explained by the separation of the PFS curves for the RIT-CHOP arm (10-year PFS 25% vs 67%; HR = 3.22; <italic>P</italic> = .0007) (<xref rid="fig2" ref-type="fig">Figure 2</xref>D).</p>
              </sec>
              <sec id="sec3.4">
                <title>RIT-CHOP prolongs PFS particularly in patients lacking <italic>TP53</italic> mutations</title>
                <p id="p0105">In this subset of patients with available specimens, the impact of the therapies is almost superimposable on the entire population as last reported<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). Considering only the 110 patients with no evidence of a <italic>TP53</italic> mutation, RIT-CHOP was associated with a longer PFS than R-CHOP (10-year PFS 67% vs 44%; HR = 0.49; <italic>P</italic> = .008; 95% CI, 0.29-0.83) (<xref rid="fig3" ref-type="fig">Figure 3</xref>B). In the corresponding subset (the 37 patients with a pathogenic <italic>TP53</italic> mutation), PFS with RIT-CHOP was not significantly different from that obtained with R-CHOP (10-year PFS 25% vs 43%; HR = 1.90; <italic>P</italic> = .09; 95% CI, 0.90-4.04) (<xref rid="fig3" ref-type="fig">Figure 3</xref>C) (refer to <xref rid="appsec1" ref-type="sec">supplemental Data</xref> for overall survival).</p>
              </sec>
              <sec id="sec3.5">
                <title>Treatment and time do not consistently affect the VAFs for <italic>TP53</italic> mutations</title>
                <p id="p0110">In the serial samples assembled in the validation cohort, the VAFs of pathogenic <italic>TP53</italic> mutations did not increase with time or therapy (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Of the 21 pathogenic <italic>TP53</italic> mutations observed at any time point, various patterns were seen including persistence, emergence, emergence with subsequent persistence, loss, and emergence with subsequent loss. Only 2 patients (patients 2 and 35) showed stable VAFs. Of the 11 <italic>TP53</italic> mutations with VAF &lt;0.1, only 1 was observed at 2 distinct time points (patient 38 C141Y). One specimen showed a complete loss of a relatively abundant <italic>TP53</italic> mutation (patient 1; mutation R110C) whereas in another a relatively high VAF <italic>TP53</italic> mutation emerged (patient 25; mutation C176R). Two patients (38 and 42) showed transformation to diffuse large B-cell lymphoma; neither case showed acquisition of a high VAF TP53 mutation. Regardless of the details of the time courses, a consistent increase in the VAF of pathogenic <italic>TP53</italic> mutation was not observed in FL treated with CHOP-based regimens.<fig id="fig4"><label>Figure 4.</label><caption><p><bold><italic>TP53</italic> mutations are evanescent and their VAF does not overtly increase with relapse.</bold> Out of 22 patients with serial specimens, 11 patients had at least 1 specimen with a pathogenic mutation. The VAFs for these mutations are shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>B FL validation. To estimate changes in tumor cell content, we determined the sum of VAFs for mutations in a single amplicon of <italic>uBCL2</italic> (solid black lines with orange blocks); this provides an estimate of the minimum tumor content. The <italic>TP53</italic> mutations are depicted on the thick gray lines (red blocks mark the VAF; blue blocks denote that the mutation was not detected at that time point [for <italic>TP53</italic>] or only germ line sequence for <italic>uBCL2</italic>).</p></caption><graphic xlink:href="BLOODA_ADV-2022-009467-gr4"/></fig></p>
              </sec>
              <sec id="sec3.6">
                <title>Intraclonal tumor genetic heterogeneity does not explain the impact of low abundance <italic>TP53</italic> mutations on the clinical course of FL</title>
                <p id="p0115">The detection of low abundance mutations in any gene might mark tumors that have an increased intratumoral genetic heterogeneity. We sought to test the alternative hypothesis that intraclonal heterogeneity itself, rather than the presence of a low abundance mutation specifically in <italic>TP53</italic>, would correlate with outcome or predict the presence of a detectable pathogenic mutation in <italic>TP53</italic>.</p>
                <p id="p0120">AICDA-mediated sequence variants in IGHV and <italic>uBCL2</italic> were used to assess intraclonal genetic heterogeneity in 147 specimens (120 IGHV and 146 <italic>u</italic><italic>BCL2</italic>) also assessed for <italic>TP53</italic> variants. Abundant AICDA-mediated mutations were present such that the clonal IGHV was highly mutated (&lt;0.98 germ line; 98/105 patients; median, 0.89; quartiles 1-3, 0.87-0.92) as was <italic>uBCL2</italic> (136/146 patients; 828 SNVs, median of 5 per specimen; range, 1-32). Mutations in <italic>uBCL2</italic> were strongly skewed to the AICDA motif (<italic>P</italic> &lt; .001) and sequences with VAFs implying that clonal dominance were common (median, 0.28; quartiles 2-3, 0.14-0.40) (<xref rid="appsec1" ref-type="sec">supplemental Table 4</xref>). Similar to our previous work, the numbers of subclones based on IGHV (range, 1-501; median, 30) and u<italic>BCL2</italic> (range, 1-32; median, 5) were highly variable; furthermore, in the 115 samples with at least 1 subclone marked by <italic>uBCL2</italic> or IGHV sequence variants, the numbers of subclones were independent of each other (<xref rid="fig5" ref-type="fig">Figure 5</xref>A).<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> The detection of a pathogenic mutation in <italic>TP53</italic> was not associated with the number of subclones detected in either <italic>uBCL2</italic> or IGHV sequences (<xref rid="fig5" ref-type="fig">Figure 5</xref>A).<fig id="fig5"><label>Figure 5.</label><caption><p><bold>The extent of AICDA-mediated diversity as marked by <italic>uBCL2</italic> and IGVH varies widely and is unrelated to the presence of a <italic>TP53</italic> mutation.</bold> (A) The number of distinct sequences for <italic>uBCL2</italic> is the maximum number seen for a single amplicon within that region (refer to Methods). The number of distinct IGVH sequences is the number of distinct variants detected in the clonal IGVH sequence (refer to Methods). Patients with no variants are scored as 1. No relationship is apparent among the number of distinct <italic>uBCL2</italic> sequences, the number of distinct IGVH sequences, and the status of <italic>TP53</italic> (filled denotes detectable pathogenic lesion; open denotes no detectable lesion). (B-C) No relationship is apparent between the number of variant uBCL2 or IGVH sequences and the time to progression or progression at any time<italic>.</italic> The number of variant IGVH and <italic>uBCL2</italic> sequences was not different between the patients who showed disease progression (blue) or who did not show disease progression (red). Furthermore, there is no suggestion that the number of sequence variants detected differed between those who showed disease progression within 2 years and those who showed disease progression later.</p></caption><graphic xlink:href="BLOODA_ADV-2022-009467-gr5"/></fig></p>
                <p id="p0125">Although the data using subclones marked by AICDA-mediated mutations in u<italic>BCL2</italic> and IGHV show that diagnostic FL specimens are composed of varying numbers of subclones, neither the number of these mutations nor the number of subclones denoted by these mutations were prognostic (<xref rid="fig5" ref-type="fig">Figure 5</xref>B; <xref rid="appsec1" ref-type="sec">supplemental File 4</xref>). Four metrics were assessed: the number of mutations present in the most mutated sequence and the number of distinct sequences detected. Cox regression showed no relationship between PFS and the maximum number of mutations in <italic>uBCL2</italic> (HR, 1; 95% CI, 0.94-1.03) or the subclone count based on u<italic>BCL2</italic> variants (HR, 1; 95% CI, 0.95-1.03). Furthermore, receiver operator curves did not suggest a cut point for any of these measures that would predict disease progression at any time (areas under the curve are indistinguishable from 0.5; <xref rid="appsec1" ref-type="sec">supplemental File 5</xref>). No relationship was observed between progression and the percent identity IGHV to germ line for the most frequent IGHV sequence in each case (HR, 0.85; 95% CI, 0.50-1.45; relative to 10% increase in percent identity) and the number of subclones defined by IGHV sequences (HR, 1.02; 95% CI, 0.99-1.04; relative to 10 counts increase in subclone). Similar results were observed when whether the subclone count was considered as a continuous variable or stratified as quartiles. Furthermore, none of these measures was associated with the likelihood of progression within 24 months, a time point used as a prognostic indicator in clinical practice.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p>
              </sec>
            </sec>
            <sec id="sec4">
              <title>Discussion</title>
              <p id="p0130">These data suggest that <italic>TP53</italic> mutations are a predictive biomarker for RIT in FL. Specifically, in patients without any detectable <italic>TP53</italic> mutation, RIT-CHOP had a substantially improved PFS compared with R-CHOP (67% vs 44%, 10-year PFS). Although tositumomab is no longer available, our results may be paradigmatic with relevance to other settings in which radiation is used.</p>
              <sec id="sec4.1">
                <title>Characteristics of subclonal <italic>TP53</italic> mutations in FL</title>
                <p id="p0135">Although <italic>TP53</italic> mutations have been described as infrequent in low grade FL, our ultradeep sequencing shows that 25% of advanced–stage FL specimens had at least 1 subpopulation with a mutation. Although the <italic>TP53</italic> mutations observed in FL are at the same hotspots as in other lymphoid malignancies, the incidence, VAFs, and time course of <italic>TP53</italic> mutations in FL appear distinctive. First, in contrast to <italic>TP53</italic> mutations in MCL and MZL, the VAF is almost uniformly low in FL. Second, multiple pathogenic <italic>TP53</italic> mutations per case were more frequent in FL specimens than in MZL or MCL, consistent with a recent study of 26 cases of MCL that reported that 1 of 9 <italic>TP53</italic> mutated specimens had &gt;1 mutation.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Third, although <italic>TP53</italic> mutant populations are reported to expand after therapy in chronic lymphocytic leukemia,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> we did not identify a single instance in which the VAF of a pathogenic <italic>TP53</italic> mutation showed an interval increase.</p>
              </sec>
              <sec id="sec4.2">
                <title>The relationship between TP53 mutation status and outcome depended on therapy</title>
                <p id="p0140">Several publications have suggested that although infrequent, high VAF <italic>TP53</italic> mutations are associated with a poor prognosis in FL and are more common in grade 3 and transformed FL.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Our salient finding is that the lack of detectable low VAF <italic>TP53</italic> mutations is associated with improved PFS for RIT-CHOP compared with that for R-CHOP (<xref rid="fig3" ref-type="fig">Figure 3</xref>B).</p>
                <p id="p0145">In contrast to patients treated on the RIT-CHOP arm, <italic>TP53</italic> mutation status did not affect PFS for patients treated with R-CHOP (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). Similarly, Pastore et al did not identify <italic>TP53</italic>-mutations as prognostic for patients treated with R-CHOP (although the methods may not have detected subclonal mutations).<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> The lack of a discernable effect of <italic>TP53</italic> mutations in the R-CHOP arm may reflect that overexpression of BCL2, a hallmark feature of FL, creates a high barrier for <italic>TP53</italic>-dependent apoptosis. A major mechanism of <italic>TP53</italic> function is induction of BAX, which in turn inhibits BCL2; even in the presence of fully functional <italic>TP53</italic>, CHOP-induced activation of BAX may be insufficient to overcome BCL2-mediated blockade of apoptosis in FL.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref></p>
                <p id="p0150">Our observation suggesting that <italic>TP53</italic> mediates response to radiotherapy is consistent with previous reports. More than a quarter century ago, Lowe et al<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> demonstrated that external beam radiation rapidly shrinks the murine thymus because of apoptosis of lymphocytes, whereas the thymic T cells of <italic>TP53</italic> knock-out mice are resistant. Knoops et al showed that the efficacy of low-dose external beam radiation in FL depends on <italic>TP53</italic>.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Therefore, functional <italic>TP53</italic> is likely the basis for the efficacy of RIT and can be considered as a predictive biomarker in this regard.</p>
              </sec>
              <sec id="sec4.3">
                <title>AICDA-mediated genetic heterogeneity does not correspond to clinical outcome</title>
                <p id="p0155">Although intraclonal genetic heterogeneity in FL is well-documented, the association of diversity and subclonal populations with outcome has not been extensively investigated. Early studies showed extensive AICDA-mediated diversification of IGHV sequences.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Furthermore, sequencing studies of serial specimens show that the dominant subclones vary over time.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Regardless, there are fewer data addressing whether the number of subclones or the type of intraclonal heterogeneity affect outcome in FL.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Although a large study has detected an association between intraclonal heterogeneity and outcome in a range of solid tumors, similar studies have not, to our knowledge, been conducted in lymphoma.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> To provide a metric of AICDA-mediated intraclonal heterogeneity, we focus on the loci most highly targeted by AICDA, <italic>uBCL2,</italic> and IGHV, in which the density of mutations is at least an order of magnitude greater than in other well-characterized AICDA targets (eg, <italic>PIM1</italic>, <italic>MYC</italic>, and <italic>BCL6</italic>).<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p>
                <p id="p0160">Neither the number of mutations in <italic>uBCL2</italic> and IGHV nor the number of subclones marked by these mutations correlated with the presence of low VAF <italic>TP53</italic> mutations. Therefore, detection of low VAF <italic>TP53</italic> mutations does not appear to be a surrogate marker for greater intraclonal genetic heterogeneity. These data suggest a paradox; although AICDA-mediated mutations are reported to be more abundant in progressed or transformed FL, we find that the level of AICDA-mediated mutation in diagnostic specimens is not related to the likelihood of subsequent progression.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Two models could resolve this paradox. AICDA-mediated mutagenesis is episodic in lymphoma cell lines in which after many cell cycles with no detectable AICDA-mediated mutagenesis, transient bursts of mutagenesis occurred in individual cells.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> In a mouse model of FL, lymphomagenesis occurred through multiple cycles of B cells through germinal centers, each cycle including episodic activation of AICDA and an opportunity to acquire additional driver mutations.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Therefore, AICDA-mediated mutagenesis may be a driver of transformation, but because it occurs intermittently, it cannot serve as a prognostic marker. Alternatively, others have suggested that AICDA-mediated epigenetic heterogeneity rather than genetic heterogeneity drives progression.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> In either case, our data refine hypotheses regarding the relationship between AICDA and progression by discrediting the hypothesis that AICDA-mediated genetic heterogeneity can serve as a prognostic marker in FL. Given the dominant role of APOBECs (apolipoprotein B messenger RNA–editing enzyme, catalytic polypeptides, the gene fanliy that includes <italic>AICDA</italic>) in sculpting the genome in a wide range of malignancies,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> our observation may have implications beyond FL.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></p>
              </sec>
              <sec id="sec4.4">
                <title>Limitations</title>
                <p id="p0165">We cannot formally exclude that clonal hematopoiesis instead of tumor-intrinsic somatic mutations was the source of the low-level TP53-mutations seen in 25% of the patients. Were the TP53 mutations due to infiltrating myeloid cells, one might suggest that the rapid progression seen in TP53-mutated subjects treated with RIT-CHOP was due to the emergence of a myelodysplasia. However, progression in this study was defined by lymphoma-specific findings. Furthermore, Bennett et al<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> explicitly addressed this issue in S0016 that no increase in marrow pathology was detected in the RIT-CHOP arm, suggesting that the shortened PFS and overall survival associated with these low VAF TP53 mutations is not due to an effect of radiation on the marrow.</p>
                <p id="p0170">Although our methods address <italic>TP53</italic> point mutations, the approach does not address alternative oncogenic mechanism, particularly deletion. Qu et al<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> studied these same samples from S0016 and reported that high VAF loss of TP53 (at least 20%-30% of alleles lost) is associated with shortened PFS. Assessing whether such copy number losses are present at VAFs similar to 0.02 (2%) in FFPE specimens which would require technologies that are currently speculative.</p>
                <p id="p0175">We could not locate another phase 3 trial collection with which to independently test whether subclonal <italic>TP53</italic> mutations represent a predictive marker for regimens including radiation. Our observation in this study depends on the decades-long stewardship of specimens and data, and the lack of a validation cohort highlights a critical limitation in trial programs. We hope that this missed opportunity stimulates funders and trialists to enhance support for the collection of trial-associated specimens.</p>
              </sec>
              <sec id="sec4.5">
                <title>Summary</title>
                <p id="p0180">Low VAF <italic>TP53</italic> mutations are predictive of therapeutic inefficacy for patients with FL treated with CHOP-RIT. The relative efficacy of RIT-CHOP compared with R-CHOP is apparent in the 75% of patients who lack a detectable <italic>TP53</italic> mutation. These observations call for enhanced precision medicine approaches through the use of deep sequencing in FL, as clinically relevant cohorts are defined not only by driver mutations but also by the mutations not found with a highly sensitive assay.</p>
              </sec>
            </sec>
            <sec sec-type="COI-statement">
              <p id="p0185">Conflict-of-interest disclosure: The authors declare no competing financial interests.</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pasqualucci</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Molecular pathogenesis of germinal center-derived B cell lymphomas</article-title>
                  <source>Immunol Rev</source>
                  <volume>288</volume>
                  <issue>1</issue>
                  <year>2019</year>
                  <fpage>240</fpage>
                  <lpage>261</lpage>
                  <pub-id pub-id-type="pmid">30874347</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pasqualucci</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Bhagat</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Jankovic</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>AID is required for germinal center-derived lymphomagenesis</article-title>
                  <source>Nat Genet</source>
                  <volume>40</volume>
                  <issue>1</issue>
                  <year>2008</year>
                  <fpage>108</fpage>
                  <lpage>112</lpage>
                  <pub-id pub-id-type="pmid">18066064</pub-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pasqualucci</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Khiabanian</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Fangazio</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genetics of follicular lymphoma transformation</article-title>
                  <source>Cell Rep</source>
                  <volume>6</volume>
                  <issue>1</issue>
                  <year>2014</year>
                  <fpage>130</fpage>
                  <lpage>140</lpage>
                  <pub-id pub-id-type="pmid">24388756</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Casulo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Burack</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Friedberg</surname>
                      <given-names>JW</given-names>
                    </name>
                  </person-group>
                  <article-title>Transformed follicular non-Hodgkin lymphoma</article-title>
                  <source>Blood</source>
                  <volume>125</volume>
                  <issue>1</issue>
                  <year>2015</year>
                  <fpage>40</fpage>
                  <lpage>47</lpage>
                  <pub-id pub-id-type="pmid">25499449</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Correia</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Dai</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma</article-title>
                  <source>Blood</source>
                  <volume>125</volume>
                  <issue>4</issue>
                  <year>2015</year>
                  <fpage>658</fpage>
                  <lpage>667</lpage>
                  <pub-id pub-id-type="pmid">25452615</pub-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Halldorsdottir</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Fruhwirth</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Deutsch</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma</article-title>
                  <source>Leuk Res</source>
                  <volume>32</volume>
                  <issue>7</issue>
                  <year>2008</year>
                  <fpage>1015</fpage>
                  <lpage>1021</lpage>
                  <pub-id pub-id-type="pmid">18180034</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Greaves</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Maley</surname>
                      <given-names>CC</given-names>
                    </name>
                  </person-group>
                  <article-title>Clonal evolution in cancer</article-title>
                  <source>Nature</source>
                  <volume>481</volume>
                  <issue>7381</issue>
                  <year>2012</year>
                  <fpage>306</fpage>
                  <lpage>313</lpage>
                  <pub-id pub-id-type="pmid">22258609</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huet</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Szafer-Glusman</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Tesson</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab</article-title>
                  <source>Am J Hematol</source>
                  <volume>92</volume>
                  <issue>6</issue>
                  <year>2017</year>
                  <fpage>515</fpage>
                  <lpage>519</lpage>
                  <pub-id pub-id-type="pmid">28247997</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Willenbrock</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Renne</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rottenkolber</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The expression of activation induced cytidine deaminase in follicular lymphoma is independent of prognosis and stage</article-title>
                  <source>Histopathology</source>
                  <volume>54</volume>
                  <issue>4</issue>
                  <year>2009</year>
                  <fpage>509</fpage>
                  <lpage>512</lpage>
                  <pub-id pub-id-type="pmid">19309412</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kridel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>FC</given-names>
                    </name>
                    <name>
                      <surname>Mottok</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Histological transformation and progression in follicular lymphoma: a clonal evolution study</article-title>
                  <source>PLoS Med</source>
                  <volume>13</volume>
                  <issue>12</issue>
                  <year>2016</year>
                  <object-id pub-id-type="publisher-id">e1002197</object-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarkozy</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Huet</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Carlton</surname>
                      <given-names>VE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma</article-title>
                  <source>Oncotarget</source>
                  <volume>8</volume>
                  <issue>5</issue>
                  <year>2017</year>
                  <fpage>8765</fpage>
                  <lpage>8774</lpage>
                  <pub-id pub-id-type="pmid">28060738</pub-id>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lossos</surname>
                      <given-names>IS</given-names>
                    </name>
                    <name>
                      <surname>Levy</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Alizadeh</surname>
                      <given-names>AA</given-names>
                    </name>
                  </person-group>
                  <article-title>AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity</article-title>
                  <source>Leukemia</source>
                  <volume>18</volume>
                  <issue>11</issue>
                  <year>2004</year>
                  <fpage>1775</fpage>
                  <lpage>1779</lpage>
                  <pub-id pub-id-type="pmid">15385936</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scherer</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Navarrete</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Bertinetti-Lapatki</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Boehm</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schmitt-Graeff</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Veelken</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation</article-title>
                  <source>Leuk Lymphoma</source>
                  <volume>57</volume>
                  <issue>1</issue>
                  <year>2016</year>
                  <fpage>151</fpage>
                  <lpage>160</lpage>
                  <pub-id pub-id-type="pmid">25860234</pub-id>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O'Shea</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>O'Riain</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival</article-title>
                  <source>Blood</source>
                  <volume>112</volume>
                  <issue>8</issue>
                  <year>2008</year>
                  <fpage>3126</fpage>
                  <lpage>3129</lpage>
                  <pub-id pub-id-type="pmid">18628487</pub-id>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rossi</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Khiabanian</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Spina</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia</article-title>
                  <source>Blood</source>
                  <volume>123</volume>
                  <issue>14</issue>
                  <year>2014</year>
                  <fpage>2139</fpage>
                  <lpage>2147</lpage>
                  <pub-id pub-id-type="pmid">24501221</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Press</surname>
                      <given-names>OW</given-names>
                    </name>
                    <name>
                      <surname>Unger</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Rimsza</surname>
                      <given-names>LM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016</article-title>
                  <source>J Clin Oncol</source>
                  <volume>31</volume>
                  <issue>3</issue>
                  <year>2013</year>
                  <fpage>314</fpage>
                  <lpage>320</lpage>
                  <pub-id pub-id-type="pmid">23233710</pub-id>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shadman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Rimsza</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016</article-title>
                  <source>J Clin Oncol</source>
                  <volume>36</volume>
                  <issue>7</issue>
                  <year>2018</year>
                  <fpage>697</fpage>
                  <lpage>703</lpage>
                  <pub-id pub-id-type="pmid">29356608</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spence</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Abumoussa</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spence</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Burack</surname>
                      <given-names>WR</given-names>
                    </name>
                  </person-group>
                  <article-title>Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions</article-title>
                  <source>J Immunol</source>
                  <volume>193</volume>
                  <issue>10</issue>
                  <year>2014</year>
                  <fpage>4888</fpage>
                  <lpage>4894</lpage>
                  <pub-id pub-id-type="pmid">25311808</pub-id>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sakhdari</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ok</surname>
                      <given-names>CY</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>KP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant</article-title>
                  <source>Ann Diagn Pathol</source>
                  <volume>41</volume>
                  <year>2019</year>
                  <fpage>38</fpage>
                  <lpage>42</lpage>
                  <pub-id pub-id-type="pmid">31132650</pub-id>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Casulo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Byrtek</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dawson</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study</article-title>
                  <source>J Clin Oncol</source>
                  <volume>33</volume>
                  <issue>23</issue>
                  <year>2015</year>
                  <fpage>2516</fpage>
                  <lpage>2522</lpage>
                  <pub-id pub-id-type="pmid">26124482</pub-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landau</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Stojanov</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evolution and impact of subclonal mutations in chronic lymphocytic leukemia</article-title>
                  <source>Cell</source>
                  <volume>152</volume>
                  <issue>4</issue>
                  <year>2013</year>
                  <fpage>714</fpage>
                  <lpage>726</lpage>
                  <pub-id pub-id-type="pmid">23415222</pub-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pastore</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jurinovic</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Kridel</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry</article-title>
                  <source>Lancet Oncol</source>
                  <volume>16</volume>
                  <issue>9</issue>
                  <year>2015</year>
                  <fpage>1111</fpage>
                  <lpage>1122</lpage>
                  <pub-id pub-id-type="pmid">26256760</pub-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miyashita</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Reed</surname>
                      <given-names>JC</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor suppressor p53 is a direct transcriptional activator of the human bax gene</article-title>
                  <source>Cell</source>
                  <volume>80</volume>
                  <issue>2</issue>
                  <year>1995</year>
                  <fpage>293</fpage>
                  <lpage>299</lpage>
                  <pub-id pub-id-type="pmid">7834749</pub-id>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lowe</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Schmitt</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Osborne</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Jacks</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>p53 is required for radiation-induced apoptosis in mouse thymocytes</article-title>
                  <source>Nature</source>
                  <volume>362</volume>
                  <issue>6423</issue>
                  <year>1993</year>
                  <fpage>847</fpage>
                  <lpage>849</lpage>
                  <pub-id pub-id-type="pmid">8479522</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Knoops</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Haas</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>de Kemp</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma</article-title>
                  <source>Blood</source>
                  <volume>110</volume>
                  <issue>4</issue>
                  <year>2007</year>
                  <fpage>1116</fpage>
                  <lpage>1122</lpage>
                  <pub-id pub-id-type="pmid">17483295</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oeschger</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Brauninger</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kuppers</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hansmann</surname>
                      <given-names>ML</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor cell dissemination in follicular lymphoma</article-title>
                  <source>Blood</source>
                  <volume>99</volume>
                  <issue>6</issue>
                  <year>2002</year>
                  <fpage>2192</fpage>
                  <lpage>2198</lpage>
                  <pub-id pub-id-type="pmid">11877297</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Okosun</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bodor</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma</article-title>
                  <source>Nat Genet</source>
                  <volume>46</volume>
                  <issue>2</issue>
                  <year>2014</year>
                  <fpage>176</fpage>
                  <lpage>181</lpage>
                  <pub-id pub-id-type="pmid">24362818</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Andor</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Graham</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Jansen</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pan-cancer analysis of the extent and consequences of intratumor heterogeneity</article-title>
                  <source>Nat Med</source>
                  <volume>22</volume>
                  <issue>1</issue>
                  <year>2016</year>
                  <fpage>105</fpage>
                  <lpage>113</lpage>
                  <pub-id pub-id-type="pmid">26618723</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petljak</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Alexandrov</surname>
                      <given-names>LB</given-names>
                    </name>
                    <name>
                      <surname>Brammeld</surname>
                      <given-names>JS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis</article-title>
                  <source>Cell</source>
                  <volume>176</volume>
                  <issue>6</issue>
                  <year>2019</year>
                  <fpage>1282</fpage>
                  <lpage>1294.e20</lpage>
                  <pub-id pub-id-type="pmid">30849372</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sungalee</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mamessier</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Morgado</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression</article-title>
                  <source>J Clin Invest</source>
                  <volume>124</volume>
                  <issue>12</issue>
                  <year>2014</year>
                  <fpage>5337</fpage>
                  <lpage>5351</lpage>
                  <pub-id pub-id-type="pmid">25384217</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Teater</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dominguez</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Redmond</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis</article-title>
                  <source>Nat Commun</source>
                  <volume>9</volume>
                  <issue>1</issue>
                  <year>2018</year>
                  <fpage>222</fpage>
                  <lpage>232</lpage>
                  <pub-id pub-id-type="pmid">29335468</pub-id>
                </element-citation>
              </ref>
              <ref id="bib32">
                <label>32</label>
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roberts</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Lawrence</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Klimczak</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers</article-title>
                  <source>Nat Genet</source>
                  <volume>45</volume>
                  <issue>9</issue>
                  <year>2013</year>
                  <fpage>970</fpage>
                  <lpage>976</lpage>
                  <pub-id pub-id-type="pmid">23852170</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <label>33</label>
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Swanton</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>McGranahan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Starrett</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>RS</given-names>
                    </name>
                  </person-group>
                  <article-title>APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity</article-title>
                  <source>Cancer Discov</source>
                  <volume>5</volume>
                  <issue>7</issue>
                  <year>2015</year>
                  <fpage>704</fpage>
                  <lpage>712</lpage>
                  <pub-id pub-id-type="pmid">26091828</pub-id>
                </element-citation>
              </ref>
              <ref id="bib34">
                <label>34</label>
                <element-citation publication-type="journal" id="sref34">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bennett</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Kaminski</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Leonard</surname>
                      <given-names>JP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab</article-title>
                  <source>Blood</source>
                  <volume>105</volume>
                  <issue>12</issue>
                  <year>2005</year>
                  <fpage>4576</fpage>
                  <lpage>4582</lpage>
                  <pub-id pub-id-type="pmid">15731177</pub-id>
                </element-citation>
              </ref>
              <ref id="bib35">
                <label>35</label>
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Qu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Braziel</surname>
                      <given-names>RM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016</article-title>
                  <source>Blood</source>
                  <volume>133</volume>
                  <issue>1</issue>
                  <year>2019</year>
                  <fpage>81</fpage>
                  <lpage>93</lpage>
                  <pub-id pub-id-type="pmid">30446494</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <p id="p0205">
                <supplementary-material content-type="local-data" id="ec1">
                  <caption>
                    <title>Supplemental Methods, References, Tables and Figures</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc1.pdf"/>
                </supplementary-material>
              </p>
              <p id="p0205a">
                <supplementary-material content-type="local-data" id="ec2">
                  <caption>
                    <title>Supplemental Figure 6</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc2.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205b">
                <supplementary-material content-type="local-data" id="ec3">
                  <caption>
                    <title>Supplemental Tables</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc3.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205c">
                <supplementary-material content-type="local-data" id="ec4">
                  <caption>
                    <title>Supplemental Figure 5</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc4.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205d">
                <supplementary-material content-type="local-data" id="ec5">
                  <caption>
                    <title>Supplemental Data</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc5.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205e">
                <supplementary-material content-type="local-data" id="ec6">
                  <caption>
                    <title>Supplemental Table 1</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc6.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205f">
                <supplementary-material content-type="local-data" id="ec7">
                  <caption>
                    <title>Supplemental Table 2</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc7.docx"/>
                </supplementary-material>
              </p>
              <p id="p0205g">
                <supplementary-material content-type="local-data" id="ec8">
                  <caption>
                    <title>Supplemental Table 3</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2022-009467-mmc8.docx"/>
                </supplementary-material>
              </p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgments</title>
              <p id="p0190">The authors recognize the late Oliver Press for his contributions to SWOG and study S0016. John Spence and Phil Rock provided essential computational and technical support. C. Ross (University of Michigan) supported efforts to locate additional specimens.</p>
              <p id="p0195">This work was supported by <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of H</institution></institution-wrap></funding-source>ealth/<funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000054</institution-id><institution>National Cancer I</institution></institution-wrap></funding-source>nstitute grants U10CA180888, U10CA180819, U10CA180821, R21CA198072 (W.R.B.), and in part by <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004330</institution-id><institution>GlaxoSmithKline</institution></institution-wrap></funding-source>.</p>
              <sec id="sec5">
                <title>Authorship</title>
                <p id="p0200">Contribution: W.R.B. designed and performed research, analyzed data, and wrote the manuscript; H.L. and M.L.L. designed research and analyzed data; D.A. designed and performed research, analyzed data, and wrote the manuscript; J.M.S. designed and performed research, and analyzed data; C.M.S. and L.M.R. performed research; S.M.S., M.S., J.P.L., and M.S.K. conducted the trial; and J.W.F. conducted the trial and wrote the manuscript.</p>
              </sec>
            </ack>
            <fn-group>
              <fn id="d35e136">
                <p id="ntpara0010">Data are available on request from the corresponding author, W. Richard Burack (<ext-link ext-link-type="uri" xlink:href="mailto:richard_burack@urmc.rochester.edu" id="intref0010">richard_burack@urmc.rochester.edu</ext-link>).</p>
              </fn>
              <fn id="d35e142">
                <p id="ntpara0015">The full-text version of this article contains a data supplement.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
